Lady Gaga Just Launched a Biotech Company. No, Seriously.
Lady Gaga and fiancé Michael Polansky just emerged from stealth with Outer Biosciences, a $23 million startup that keeps human skin alive in a lab for weeks to discover skincare ingredients with AI. It's weirder (and more legit) than it sounds.
A Pop Star Walks Into a Lab
Somewhere in the vast middle ground between "Bad Romance" and biotech lies a sentence nobody expected to write: Lady Gaga co-founded a life sciences company. And it's not a celebrity wellness brand hawking overpriced supplements. It's a startup that keeps chunks of human skin alive in a lab for a month.
The company is called Outer Biosciences, and it just came out of stealth after operating quietly since 2020. Gaga's fiancé, Michael Polansky, is the co-founder and CEO. The company has raised roughly $23 million from backers including Wing Ventures, Initialized, and Polansky's own firm, Hawktail. And the pitch is genuinely interesting, even if you strip away every ounce of celebrity glitter.
What Outer Biosciences Actually Does
Imagine you're a skincare company trying to figure out if a new ingredient actually works. Traditionally, you'd test it on lab-grown cells (which don't behave like real skin), on animals (increasingly banned), or on human volunteers (expensive and slow). None of those options are great.
Outer's platform, called Yuna, takes a different approach. The company acquires donated surgical tissue, often from plastic surgery procedures, and keeps that full-thickness human skin alive and functional outside the body for about four weeks. That's not a typo. We're talking real, living human skin sitting in a lab, maintaining its natural architecture: layers, immune cells, the whole lasagna.
Researchers can then test thousands of compounds directly on this tissue and watch what happens in real time. Think of it like a flight simulator for skincare ingredients. You get realistic results without crashing an actual plane.
The company pairs this tissue platform with AI models that learn from the data and predict which ingredients are most likely to work. The focus areas include aging, inflammation, wound healing, and collagen remodeling. For now, the target is cosmetic and skincare ingredient discovery, not FDA-regulated drugs. Outer wants to find promising compounds and license them to beauty and personal care companies.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The Guy Behind the Curtain
Polansky isn't some random celebrity spouse playing scientist. His background is more interesting than that.
He studied applied mathematics and computer science at Harvard, then spent time at Bridgewater Associates (the world's largest hedge fund) and Founders Fund (Peter Thiel's VC firm). He later ran Sean Parker's family office, which put him at the center of Parker's philanthropic and life sciences empire.
That connection is the key. He sits on the board of the Parker Institute for Cancer Immunotherapy (PICI), a nonprofit that channels hundreds of millions of dollars into cancer research.
By his own account, Polansky "got into life sciences accidentally" through more than a decade working alongside Parker in cancer immunotherapy. It wasn't a planned career path; it was osmosis. Spending years in rooms with top cancer researchers apparently rubs off on you.
Outer Biosciences was co-founded alongside Kyung-Jin Jang (the company's chief scientist), Chris Hinojosa, and Stanley King. Notably, Jang also sits on the scientific advisory board of Haus Labs, Gaga's beauty brand, and the two companies have already run joint projects together. That's a tidy pipeline: Outer discovers ingredients, Haus Labs potentially uses them.
Where Does Lady Gaga Fit In?
Gaga is listed as a co-founder and board member of Outer Biosciences, not as its scientist-in-chief. Her role appears to be strategic and promotional rather than technical, which is exactly what you'd want from someone with a massive social media following and a beauty brand.
Her broader health footprint comes through the Born This Way Foundation, a youth mental health nonprofit she launched years ago. That organization is research-informed (it developed a Kindness and Bravery Scale with the University of Nebraska-Lincoln), but it's not biotech. The connection to Outer is less about science credentials and more about what Gaga brings to the table: attention, distribution, and a massive consumer audience for whatever ingredients the platform eventually produces.
The Celebrity Biotech Trend (and Why You Should Be Skeptical)
Gaga and Polansky aren't operating in a vacuum. Celebrity money has been flooding into health and longevity startups over the past two years.
Tally Health, a consumer longevity company, counts John Legend, Chrissy Teigen, Pedro Pascal, Kevin Hart, and Zac Efron among its backers. Function raised $53 million in a 2024 Series A with support from Matt Damon and others. Superpower pulled in $30 million with investors including Vanessa Hudgens, Steve Aoki, and Giannis Antetokounmpo.
Spot the pattern? Lots of famous names. Lots of funding rounds. Very little published clinical proof.
The core risk with celebrity biotech is simple: fame can masquerade as validation. Consumers see a famous face and assume the science must be solid. That's not how evidence works. A seed round and a press hit are not substitutes for reproducible data and peer review.
Outer Biosciences has at least posted a bioRxiv preprint describing its tissue platform. That's more scientific disclosure than most celebrity-adjacent health companies have offered. But preprints are not peer-reviewed, and company-reported results haven't been independently validated yet. The science looks plausible; it just hasn't been stress-tested by outside researchers.
So Is This the Real Deal?
Honestly? It's too early to say, but there are reasons to pay attention.
The bull case: Outer is solving a real problem in skincare R&D. Testing on living human tissue is better than testing on plastic dishes. AI-driven ingredient discovery could dramatically speed up a process that currently takes years. And the team has legitimate biotech and life sciences experience, not just celebrity wattage.
The bear case: the company is still pre-commercial. It hasn't proven that its AI predictions translate into ingredients that outperform what existing methods find. The cosmetics market is notoriously hype-driven, and having Lady Gaga's name attached could generate buzz that outpaces the underlying science.
Polansky has reportedly declined to say whether Outer is currently raising more money, which suggests the company is still in growth mode rather than anywhere near profitability.
The most honest take? This is a legitimate biotech platform wrapped in a celebrity headline. The science is real, even if it's early. The team has credible experience. But the gap between "promising tissue model" and "reliable ingredient discovery engine" is wide, and no amount of star power can close it. Only data can.
For now, the biotech world gets its most unexpected founder since… well, since ever. And somewhere, a VC is trying to figure out how to put "backed by the same team as 'Poker Face'" into a pitch deck.
Clinical & Regulatory
4 min read
A Robot Just Drew Blood for the First Time in U.S. History
The FDA just authorized the first-ever robotic blood-draw device in the U.S., and it nails hard-to-find veins better than most humans. Vitestro's Aletta could reshape everything from clinical trials to your next lab visit.
